2024
Perspectives on benefits and risks of creation of an “injection drug use” billing code
Sundaram G, Sato T, Goodman-Meza D, Haddad M, Thakarar K, Feinberg J, Springer S, Barton K, Butler N, Eaton E, Wurcel A. Perspectives on benefits and risks of creation of an “injection drug use” billing code. Journal Of Substance Use And Addiction Treatment 2024, 164: 209392. PMID: 38735482, DOI: 10.1016/j.josat.2024.209392.Peer-Reviewed Original ResearchInjection drug useSubstance use disordersInternational Classification of DiseasesIncreased riskICD-10 codesDrug useClassification of DiseasesHealthcare utilizationHealth servicesIncreased risk of overdoseFinancial reimbursementInternational ClassificationHealthcare systemRisk of overdoseTreatment servicesICD codesIdentifying peopleWell-beingPWIDUse disorderSystem of resource allocationHealthRiskImproved systemPotential benefits
2021
Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder
Seval N, Frank CA, Litwin AH, Roth P, Schade MA, Pavlicova M, Levin FR, Brady KT, Nunes EV, Springer SA. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. Contemporary Clinical Trials 2021, 105: 106394. PMID: 33838307, PMCID: PMC8172465, DOI: 10.1016/j.cct.2021.106394.Peer-Reviewed Original ResearchConceptsOpioid use disorderInfectious disease treatmentUse disordersCo-occurring opioid use disorderTreatment of OUDLife-threatening infectious diseaseSubstantial healthcare utilizationProportion of patientsInfectious disease specialistsInjection drug usePrimary outcome measureIntegrated care modelDisease treatmentMulti-site trialInjectable buprenorphineOpioid useSecondary outcomesHealthcare utilizationInfection morbidityDisease specialistsMedication treatmentSerious infectionsMonthly formulationDrug overdoseID specialists
2013
Partner violence and health among HIV-infected jail detainees
Meyer JP, Wickersham JA, Fu JJ, Brown SE, Sullivan TP, Springer SA, Altice FL. Partner violence and health among HIV-infected jail detainees. International Journal Of Prison Health 2013, 9: 124-141. PMID: 24376468, PMCID: PMC3873166, DOI: 10.1108/ijph-03-2013-0011.Peer-Reviewed Original ResearchConceptsIntimate partner violenceSubstance use disordersHIV treatment outcomesHealthcare utilizationPartner violenceTreatment outcomesJail detaineesIPV exposureEffects of IPVHIV secondary preventionPost-release interventionsUntreated mental disordersDepth qualitative interviewsLifetime IPV exposureForms of childhoodHigher alcohol use severityCriminal justice populationsAlcohol use severityViolence reductionCJ populationsTime of incarcerationHIV diagnosisSecondary preventionAdulthood abuseQualitative interviews
2011
Substance Abuse, Violence, and HIV in Women: A Literature Review of the Syndemic
Meyer JP, Springer SA, Altice FL. Substance Abuse, Violence, and HIV in Women: A Literature Review of the Syndemic. Journal Of Women's Health 2011, 20: 991-1006. PMID: 21668380, PMCID: PMC3130513, DOI: 10.1089/jwh.2010.2328.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHIV/AIDSSubstance abuseHealthcare utilizationPoor HIV outcomesBetter health outcomesEvidence-based interventionsNegative health consequencesHIV outcomesHIV statusMedication adherenceHealth outcomesMental illnessHealth consequencesMental healthUrban womenWomenHIVBidirectional relationshipVulnerable groupsAIDSPrevention of violenceCurrent findingsAdherenceFuture studiesInconsistent definitions